Telomir Pharmaceuticals (TELO) Competitors $2.13 -0.16 (-6.99%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.19 +0.06 (+2.77%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. GOSS, TSVT, RNAC, NGNE, DBVT, PVLA, GLUE, INZY, ALLO, and CRVSShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Gossamer Bio (GOSS), 2seventy bio (TSVT), Cartesian Therapeutics (RNAC), Neurogene (NGNE), DBV Technologies (DBVT), Palvella Therapeutics (PVLA), Monte Rosa Therapeutics (GLUE), Inozyme Pharma (INZY), Allogene Therapeutics (ALLO), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Gossamer Bio 2seventy bio Cartesian Therapeutics Neurogene DBV Technologies Palvella Therapeutics Monte Rosa Therapeutics Inozyme Pharma Allogene Therapeutics Corvus Pharmaceuticals Telomir Pharmaceuticals (NASDAQ:TELO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership. Does the MarketBeat Community favor TELO or GOSS? Gossamer Bio received 155 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Telomir Pharmaceuticals an outperform vote while only 67.09% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformTelomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo VotesGossamer BioOutperform Votes15767.09% Underperform Votes7732.91% Do analysts recommend TELO or GOSS? Telomir Pharmaceuticals currently has a consensus price target of $15.00, suggesting a potential upside of 604.23%. Gossamer Bio has a consensus price target of $7.75, suggesting a potential upside of 573.91%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than Gossamer Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TELO or GOSS more profitable? Gossamer Bio's return on equity of -127.28% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -1,170.58% -832.67% Gossamer Bio N/A -127.28%-22.12% Does the media prefer TELO or GOSS? In the previous week, Gossamer Bio had 13 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 17 mentions for Gossamer Bio and 4 mentions for Telomir Pharmaceuticals. Gossamer Bio's average media sentiment score of 0.58 beat Telomir Pharmaceuticals' score of 0.56 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, TELO or GOSS? Telomir Pharmaceuticals has higher earnings, but lower revenue than Gossamer Bio. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.42-5.07Gossamer Bio$114.70M2.28-$179.82M-$0.23-5.00 Which has more volatility & risk, TELO or GOSS? Telomir Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Do institutionals and insiders believe in TELO or GOSS? 81.2% of Gossamer Bio shares are held by institutional investors. 6.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryGossamer Bio beats Telomir Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.40M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-3.678.9226.7719.71Price / SalesN/A253.80393.17117.39Price / CashN/A65.8538.2534.62Price / Book106.506.466.794.50Net Income-$16.53M$143.98M$3.23B$248.18M7 Day Performance-9.75%2.03%1.53%0.20%1 Month Performance-18.08%4.11%10.06%12.37%1 Year Performance-61.96%-2.87%16.74%7.04% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals1.7156 of 5 stars$2.13-7.0%$15.00+604.2%-62.6%$63.40MN/A-3.671News CoverageGOSSGossamer Bio3.7737 of 5 stars$1.18+8.3%$7.75+556.8%+71.6%$268.12M$114.70M-3.69180Earnings ReportAnalyst RevisionGap UpTSVT2seventy bio1.5432 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440RNACCartesian Therapeutics1.5334 of 5 stars$10.23-1.4%$42.50+315.4%-62.3%$265.51M$34.17M-0.1964News CoverageAnalyst RevisionNGNENeurogene2.5223 of 5 stars$18.55-5.0%$44.60+140.4%-46.2%$264.56M$925,000.00-4.2690Analyst ForecastGap UpDBVTDBV Technologies2.7867 of 5 stars$9.60-11.1%$15.50+61.5%+48.6%$262.94M$15.73M-2.1380Gap DownPVLAPalvella Therapeutics3.8009 of 5 stars$23.23+3.0%$46.29+99.2%N/A$256.53M$42.81M-1.92N/AEarnings ReportAnalyst RevisionGLUEMonte Rosa Therapeutics2.1838 of 5 stars$4.16+1.2%$15.50+272.6%-6.6%$255.88M$159.49M-2.2790Positive NewsINZYInozyme Pharma2.8803 of 5 stars$3.95-1.0%$11.75+197.5%-16.0%$255.02MN/A-2.5350High Trading VolumeALLOAllogene Therapeutics3.4446 of 5 stars$1.16+6.4%$8.44+628.0%-58.7%$253.73M$22,000.00-0.74310Analyst RevisionGap UpCRVSCorvus Pharmaceuticals2.3989 of 5 stars$3.68+1.7%$15.00+307.6%+66.5%$250.86MN/A-3.9630Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Gossamer Bio Alternatives 2seventy bio Alternatives Cartesian Therapeutics Alternatives Neurogene Alternatives DBV Technologies Alternatives Palvella Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Inozyme Pharma Alternatives Allogene Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TELO Stock Free TELO Stock Alerts